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Abstract
Family with sequence similarity 20,-member C (FAM20C) is highly expressed in the mineralized tissues of mammals. Genetic
studies showed that the loss-of-function mutations in FAM20C were associated with human lethal osteosclerotic bone
dysplasia (Raine Syndrome), implying an inhibitory role of this molecule in bone formation. However, in vitro gain- and loss-
of-function studies suggested that FAM20C promotes the differentiation and mineralization of mouse mesenchymal cells
and odontoblasts. Recently, we generated Fam20c conditional knockout (cKO) mice in which Fam20c was globally
inactivated (by crossbreeding with Sox2-Cre mice) or inactivated specifically in the mineralized tissues (by crossbreeding
with 3.6 kb Col 1a1-Cre mice). Fam20c transgenic mice were also generated and crossbred with Fam20c cKO mice to
introduce the transgene in the knockout background. In vitro gain- and loss-of-function were examined by adding
recombinant FAM20C to MC3T3-E1 cells and by lentiviral shRNA–mediated knockdown of FAM20C in human and mouse
osteogenic cell lines. Surprisingly, both the global and mineralized tissue-specific cKO mice developed hypophosphatemic
rickets (but not osteosclerosis), along with a significant downregulation of osteoblast differentiation markers and a dramatic
elevation of fibroblast growth factor 23 (FGF23) in the serum and bone. The mice expressing the Fam20c transgene in the
wild-type background showed no abnormalities, while the expression of the Fam20c transgene fully rescued the skeletal
defects in the cKO mice. Recombinant FAM20C promoted the differentiation and mineralization of MC3T3-E1 cells.
Knockdown of FAM20C led to a remarkable downregulation of DMP1, along with a significant upregulation of FGF23 in
both human and mouse osteogenic cell lines. These results indicate that FAM20C is a bone formation ‘‘promoter’’ but not
an ‘‘inhibitor’’ in mouse osteogenesis. We conclude that FAM20C may regulate osteogenesis through its direct role in
facilitating osteoblast differentiation and its systemic regulation of phosphate homeostasis via the mediation of FGF23.
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Introduction
FAM20C is a member of the ‘‘family with sequence similarity
20’’. In mammals, this evolutionarily conserved protein family
consists of three members: FAM20A, FAM20B and FAM20C.
FAM20A was originally observed in the lung and liver and
displays obvious differential expression in hematopoietic cells
undergoing myeloid differentiation [1]. A viral mRNA transgenic
mouse line with an accidental deletion of a 58-kb fragment in
chromosome 11E1 encompassing part of the Fam20a gene and its
upstream region showed growth disorder [2]. Recently, it was
found that FAM20A is also expressed in ameloblasts and its
mutations are associated with human amelogenesis imperfecta and
gingival hyperplasia syndrome [3]. More recently, FAM20B was
shown to be involved in cartilage matrix production and the
ultimate regulation on the timing of skeletal development [4].
FAM20C is highly expressed in the mineralized tissues and
identified as the causal gene for lethal osteosclerotic bone dysplasia
(Raine Syndrome, OMIM 259775) [1,5–7]. Given the high level
of conservation in the C-terminal domains among the three
FAM20 members and the their roles observed in the hard tissues,
it is tempting to speculate that this evolutionarily conserved family
might be a new cluster of molecules performing important
functions in the development of the mineralized tissues.
Mouse FAM20C, also known as ‘‘dentin matrix protein 4’’
(DMP4) [5], contains 579 amino acid residues, including a
putative 26-amino acid signal peptide at the N-terminus. A C-
terminal region of approximately 350 amino acids (corresponding
to residue218-residue569 in the mouse FAM20C sequence) has been
named the ‘‘conserved C-terminal domain’’ (CCD), which is
highly conserved among different species [1].
In a previous study, we systematically analyzed the expression
and distribution of FAM20C in mouse bone and tooth using in situ
hybridization (ISH) and immunohistochemistry (IHC) methods
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[7], which showed that FAM20C was highly expressed in the
mineralized tissues; it was detected in the osteoblasts/osteocytes,
odontoblasts, ameloblasts, and cementoblasts, as well as in the
matrices of bone, dentin, and enamel. FAM20C was also detected
in the epithelium of early-stage tooth germs and in the
chondrogenic cells of long bones. The high expression levels of
FAM20C in the mineralized tissues strongly suggest that it may
play an important role in the formation and/or mineralization of
these tissues.
Hao et al. showed that overexpression of mouse FAM20C
accelerated the odontoblast differentiation process and silencing
this molecule by siRNA inhibited cell differentiation, implying that
this protein may be a factor promoting odontoblast differentiation
[5]. Subsequently, Simpson et al. reported that the loss-of-function
mutations in the FAM20C gene were associated with lethal/non-
lethal osteosclerotic bone dysplasia (Raine Syndrome) [6,8], an
autosomal recessive disorder characterized by a generalized
increase in the density of all bones; these data indicated that
FAM20C might be a down-regulator of biomineralization, which
apparently contradicts the mineralization-promoting properties of
FAM20C observed by Hao et al.
In this study, we sought to determine the biological functions of
FAM20C via generation and characterization of Fam20c condi-
tional knockout (cKO) mice. Our data showed remarkable skeletal
defects, along with a significant reduction of serum phosphate and
a dramatic elevation of serum fibroblast growth factor 23 (FGF23)
in the homozygous Fam20c cKO mice. The phenotypic profiles of
the Fam20c-deficient mice resemble those of hereditary hypophos-
phatemic rickets in humans and rodents resulting from mutations
in molecules affecting the regulation of FGF23 [9–15].
Results
Validation of FAM20C inactivation in conditional
knockout mice
The mouse Fam20c gene consists of 10 exons and spans
approximately 55-kb. To generate a conditional knockout allele
for Fam20c, we constructed a targeting vector with loxP sites
floxing exons 6,9 which are highly conserved across species
(Figure 1A); a number of mutations were identified in this region of
the human FAM20C gene in patients with lethal osteosclerotic
bone dysplasia [6]. The correct targeting events were confirmed by
polymerase chain reaction (PCR) screening, and the presence of 59
and 39 loxP sites was determined by PCR product sequencing.
Two correctly targeted ES cell clones were identified (Figure 1B,
Clones 286 and 297), and both went through germline transmis-
sion. F1 Fam20cflox/+ heterozygous mice were crossbred with Sox2
promoter-Cre transgenic mice to generate ‘‘Sox2-Cre-Fam20cD/D’’
mice, in which exons 6,9 were removed from both alleles of the
Fam20c gene in the epiblasts at post coitum day 6.5 (E6.5). The
presence of the floxed alleles and the absence of exons 6,9 in the
null alleles were confirmed by PCR genotyping (Figure 1C).
The lack of Fam20c mRNA in the Sox2-Cre-Fam20cD/D mice was
shown by reverse transcription PCR (RT-PCR) performed with
two sets of primers using mRNA extracted from the long bones
(Figure 2A), as well as by in situ hybridization (ISH) carried out on
the long bones (Figure 2B). The lack of FAM20C protein was
determined by immunohistochemistry (IHC) analyses (Figure 2C)
performed on the long bones using an affinity-purified anti-
FAM20C polyclonal antibody [7].
Both male and female Sox2-Cre-Fam20cD/D (homozygous cKO)
mice are infertile, while the Sox2-Cre-Fam20cD/+ (heterozygous
cKO) mice have normal fertility. The Fam20cflox/flox mice and the
heterozygous cKO mice did not demonstrate any phenotypic
changes compared with their wild type (WT) littermates (data not
shown), while the homozygous cKO mice displayed remarkable
skeletal defects, indicating that the haploinsufficiency of Fam20c
has no significant effects on the bone formation. We also bred the
Fam20cflox/flox mice with the 3.6 kb Col 1a1-Cre mice to generate
Col1a1-Cre-Fam20cD/D mice, which displayed skeletal defects
similar to those observed in the Sox2-Cre-Fam20cD/D mice. In this
report, we described in detail the analyses of phenotypic changes
in the Sox2-Cre-Fam20cD/D mice while the X-ray and histology data
of the long bone from the Col1a1-Cre-Fam20cD/D mice were
included in one set of the figures to show the similarity between the
global and mineralized tissue-specific cKO mice. The data
regarding the Fam20c cKO mice refer to the analyses of the
Sox2-Cre-Fam20cD/D mice unless otherwise stated.
Inactivation of FAM20C leads to skeletal defects
Inactivation of FAM20C leads to growth retardation. At
the gross level, the 4-week-old Sox2-Cre-Fam20cD/D mice demon-
strated prominent dwarfism and flat faces (Figure 3A and 3B). The
body weight of the Fam20C-deficient mice was significantly lower
than that of their WT littermates, indicating retardation in the
growth of the mutant mice (Figure 3C). X-ray examination
showed that the 5-month-old Sox2-Cre-Fam20cD/D mice had
smaller skeletons, lower levels of mineralization and distorted
spines (Figure 3D). The Alizarin Red/Alcian Blue staining of the
skeletons from 1-week-old mice revealed that the Sox2-Cre-
Fam20cD/D mice had smaller stature (Figure 4A), delayed
ossification in the ribs (Figure 4B), long bones (Figure 4C) and
carpus (Figure 4D), along with smaller skulls and delayed cranial
suture closure (Figure 4E). These observations indicated that the
Fam20c-deficient mice had extensive defects in both endochondral
and intramembranous ossifications, resulting in a generalized
hypomineralization in the axial skeleton and craniofacial complex.
Inactivation of FAM20C leads to rickets/osteo-
malacia. Plain X-ray examination did not reveal obvious
skeletal abnormalities in the Sox2-Cre-Fam20cD/D mice at birth
(data not shown). However, the bone defects in the Sox2-Cre-
Author Summary
A recent study demonstrated that the inactivating muta-
tions in the FAM20C gene were associated with lethal
osteosclerotic bone dysplasia characterized by a general-
ized hardening of all bones; this observation implied an
inhibitory role of FAM20C during bone formation. Howev-
er, in vitro studies revealed a contradictory finding that
FAM20C accelerated the differentiation of cells forming the
mineralized tissues. Here we generated Fam20c condition-
al knockout (cKO) mice, in which the gene was inactivated
either in all tissues or specifically in the mineralized tissues.
We also generated recombinant FAM20C protein and
Fam20c transgenic mice. The cKO mice did not mimic the
human skeleton abnormalities of osteosclerotic bone
dysplasia, but exhibited rickets (softer bone) along with a
significant reduction of serum phosphate level and a
remarkable elevation of serum FGF23, a hormone known
to promote phosphate wasting. A number of differentia-
tion markers of the bone-forming cells were downregu-
lated in the cKO mice. Recombinant FAM20C promoted
the differentiation of mouse preosteoblasts. Introducing
the Fam20c transgene did not lead to any abnormalities
but rescued the bone defects of the cKO mice. Taken
together, we conclude that FAM20C promotes the
differentiation of osteoblast lineages and regulates phos-
phate homeostasis via the mediation of FGF23.
FAM20C Promotes Bone Formation
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Fam20cD/D mice could be easily identified by X-ray radiography
after postnatal 4 days, and the phenotypic changes in the skeleton
became more profound as the animals aged. Multiple fractures
were often seen in the Sox2-Cre-Fam20cD/D mice after the age of 3
weeks (data not shown). At the age of 6 weeks, X-ray radiography
revealed lower density in the bones of the Sox2-Cre-Fam20cD/D
(global cKO) mice (indicating a lower level of mineralization),
along with a delay of the secondary ossification centers in the
epiphysis in the long bones (left image in Figure 5A) and vertebrae
(left image in Figure 5B). Similar bone defects were observed in the
3.6 kb Col1a1-Cre induced mineralized tissue-specific cKO mice
(middle image in Figure 5A). In addition to the delayed
ossification, micro-CT (m-CT) analyses showed increased porosity
in the diaphyses and malformed epiphyses of the global cKO mice
(Figure 5C and 5D). The appearance of more porous areas in both
the outer and inner bone surfaces of the mutant mice seen in the
m-CT radiogram was a result of increased areas of hypominer-
alization. The m-CT quantitative analyses showed a significantly
lower mineral Apparent Density and Material Density in the tibia
midshaft region of the 3-week- and 6-week-old global cKO mice
(Table 1).
Histological analyses with H&E staining showed that the long
bone of the global cKO mice had a thinner cortical bone along
with a reduced proliferative zone and an enlarged hypertrophic
zone in the growth plates (left image in Figure 5E–5G). Similar
histological defects were observed in the Col1a1-Cre induced
mineralized tissue-specific cKO mice (middle image in Figure 5E–
5G). Goldner’s Masson Trichrome staining showed that the
diaphysis region of the tibia in the Sox2-Cre-Fam20cD/D mice had
more osteoid/hypomineralized areas (stained red) in the cortical
bones (Figure 6A and 6B). The broad areas with larger amounts of
osteoid/hypomineralized tissues in the Sox2-Cre-Fam20cD/D
showed a remarkable increase in the immunostaining for biglycan
(Figure 6C and 6D) [16]. The double fluorochrome labeling
analyses showed that the Sox2-Cre-Fam20cD/D mice had a
significantly lower mineral deposition rate compared with their
WT littermates (Figure 6E and 6F). Taken together, the
phenotypic changes in the skeletons of the global and mineralized
tissue-specific cKO mice were consistent with a diagnosis of
rickets/osteomalacia.
Inactivation of FAM20C leads to defects in the growth
plate. X-ray analyses revealed hypomineralized metaphysis and
growth plate in the Sox2-Cre-Fam20cD/D mice (Figure 5A–5D).
Histological examination displayed an altered thickness of the
proliferative and hypertrophic zones in the long bones of the Sox2-
Cre-Fam20cD/D mice (Figure 5F). To determine the molecular
changes associated with the growth plate defects, we examined the
differentiation, proliferation and apoptosis of the chondrocytes in
the growth plates. In situ hybridization (ISH) analyses showed that
type IIa collagen (differentiation marker of proliferating and
mature chondrocytes) and type X collagen (differentiation marker
of hypertrophic chondrocytes) were downregulated in the growth
plates of the Sox2-Cre-Fam20cD/D mice (Figure 7A–7D), indicating
that both the early stage differentiation and the late-stage
Figure 1. Generation of the Fam20c floxed alleles and Fam20c null alleles. (A) Targeting construct. Dark boxes: Exons; dark triangles: loxP
sites. A mcl-neo cassette flanked by Frt sites (white triangles) was inserted between exons 9 and 10. A PGK-DTA cassette was downstream to the 39
homologous arm. The mcl-neo cassette was removed from the targeted allele after correct targeting. (B) PCR screening for targeted ES clones. The
correct targeting was confirmed by PCR using 59 screen primers (59S-F and 59S-R) and 39 screen primers (39S-F and 39S-R). The correct targeting
produced a 5.2 kb fragment for the 59 screening, and a 4.5 kb fragment for the 39 screen. WT and random insertion had no PCR products. Two
correctly targeted ES clones (Clone 286 and Clone 297) were identified and both went through germline transmission. (C) Genotyping strategy. The
alleles were genotyped by PCR using a mixture of three primers: ‘‘a’’, ‘‘b’’ and ‘‘c’’ (see Figure 1A). The primers ‘‘a’’ and ‘‘b’’ produced a 400 bp
fragment for the floxed allele. The primers ‘‘a’’ and ‘‘c’’ produced a 500 bp fragment for WT allele. The null alleles did not produce any PCR products
due to the loss of the binding sequences for primer ‘‘a’’. The Cre-loxP recombination was confirmed by PCR using primers Rec-F and Rec-R. A 260 bp
fragment was produced for the null allele, but no PCR products for the WT allele. Lane 1 indicated the Fam20cflox/flox genotype. Lane 2 referred to the
Fam20cflox/+. Lane 3 indicated the Fam20cD/D. Lane 4 demonstrated the WT. Lane 5 showed the Cre-LoxP recombination on Fam20c floxed allele.
doi:10.1371/journal.pgen.1002708.g001
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Figure 3. Gross defects in the Sox2-Cre-Fam20c-cKO mice. (A) The 4-week-old Sox2-Cre-Fam20cD/D (cKO) mouse on the left was smaller
compared with the WT littermate on the right. (B) The 4-week-old cKO mouse (left) had flat face (undeveloped nose, a typical manifestation of rickets)
compared with the WT littermate (right). (C) Body weight monitoring from newborn (Nb) to postnatal 10 weeks revealed significant growth
retardation in the cKO mice. (D) Plain X-ray examination of a 5-month-old cKO mouse (left) revealed smaller skeleton, hypomineralization and
distorted spine (arrowheads) compared with its WT littermate (right).
doi:10.1371/journal.pgen.1002708.g003
Figure 2. Validation of FAM20C inactivation. (A) RT-PCR was performed with the cDNAs reversely transcripted from the total RNAs extracted
from the femurs of 3-week-old Sox2-Cre-Fam20cD/D (cKO) mice and WT littermates, using two sets of primers: Set 1 primers (the forward primer was in
exon 4, and the reverse in exon 7) produced a 388 bp fragment for WT mice, and gave rise to no product from the cKO mice (due to exon 7 ablation);
Set 2 primers (the forward in exon 4, and the reverse in exon 10) produced a 840 bp fragment for the WT mice, and a 405 bp fragment for the cKO
mice. (B) ISH on femurs. The osteoblasts in the trabecular bone area of 3-week-old cKO mice had negative staining for Fam20c mRNA (left), in contrast
with the strong staining in the WT mice (right). (C) IHC on femurs. The osteoblasts and osteocytes of cKO mice (left) showed negative staining for
FAM20C protein, while positive staining was observed in the WT littermates (right). Scale bars: 50 mm.
doi:10.1371/journal.pgen.1002708.g002
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maturation of chondrocytes were affected. BrdU labeling revealed
that the absolute number of labeled proliferating chondrocytes in
the Sox2-Cre-Fam20cD/D mice was lower (Figure 7E and 7F), but
there was no statistical difference in the ratio of BrdU labeled cells
to the total number of cells in the proliferative zone between the
mutant mice and their WT littermates (data not shown). TUNEL
assay showed that the percentage of apoptotic chondrocytes in the
hypertrophic zone was reduced by ,70% in the Sox2-Cre-
Fam20cD/D mice (Figure 7G and 7H), which was consistent with
the reports that hypophosphatemia impairs caspase-mediated
apoptosis in hypertrophic chondrocytes [17,18]. The reduction of
apoptosis might be responsible for the formation of a thicker
growth plate in the cKO mice.
Inactivation of FAM20C leads to cell differentiation
defects
The osteocytes in Fam20cD/D mice lost normal morphology and
appeared immature as shown by resin-casted scanning electron
microscopy (SEM) analyses (Figure 8A and 8B), indicating a faulty
maturation process from osteoblasts to osteocytes. Backscatter
SEM analyses revealed periosteocytic lesions (‘‘halo’’) surrounding
the osteocytes in the Fam20c cKO mouse bone (Figure 8C and
8D). To determine the molecular changes associated with the
immaturity of osteoblasts/osteocytes, we examined their terminal
differentiation markers: type Ia collagen, dentin matrix protein 1
(DMP1), and osteocalcin (OCN). ISH (Figure 8E–8J), and real-
time PCR analyses (Table 2) revealed a significant downregulation
of these markers in the Sox2-Cre-Fam20cD/D mice. Microarray
analyses using total RNA extracted from the calvaria of 3-week-old
Sox2-Cre-Fam20cD/D mice and their WT littermates indicated that
among the ,45,000 molecules evaluated, 350 genes were
upregulated by over 2.0 folds and 185 were downregulated.
Real-time PCR analyses on selected genes confirmed the
significant changes in a number of biomineralization regulators
and key players in the Wnt and TGF-b signaling pathway
associated with cell differentiation (Table 2) [9–15,19–27],
suggesting an essential role of FAM20C in the differentiation
and mineralization of osteogenic cells. Notably, the most striking
transcriptional alteration was FGF23 (upregulated by ,110 folds),
a phosphorus regulator mainly produced by osteoblasts/osteocytes
[11,28,29]. Immunohistochemistry against FGF23 confirmed the
dramatic elevation in the bone cells and bone matrix of Fam20c
cKO mice (Figure 8K and 8L). The transcript levels of the above
genes in the Sox2-Cre-Fam20cD/+ (heterozygous cKO) mice showed
no difference from the WT mice (data not shown). Given the many
similarities among the Fam20c cKO mice, Dmp1 KO mice and
Hyp mice, we examined the expression levels of Fam20c in the
Dmp1- and Phex- deficient mice, and the levels of Dmp1 and Phex in
the Fam20c cKO mice by real-time PCR analyses. The Fam20c
expression was not altered in the Dmp1 KO mice and Hyp mice
(data not shown). The expression of Dmp1 was significantly
downregulated (Table 2, Figure 8) while that of Phex was not
affected (data not shown) in the Fam20c cKO mice. Ectonucleotide
pyrophosphatase/phosphodiesterase (Enpp1), another molecule
involved in regulating phosphorus homeostasis was slightly
downregulated in the bone of the Fam20c cKO mice, but the
Figure 4. Alizarin red/alcian blue staining of the skeleton in the 1-week-old Sox2-Cre-Fam20c-cKO mice. (A) The Sox2-Cre-Fam20cD/D
(cKO) mice (upper) showed smaller size and remarkably delayed ossification (more blue staining) in all bones (arrowheads) when compared with WT
littermates (lower). (B) The rib cartilages of cKO mice (upper) stained blue, while those of their WT littermates (lower) showed broad areas with the red
staining indicating ossification (arrowheads), suggesting an aberrant endochondral ossification in the cKO mice. (C) The femur of cKO mice (left) had
shorter length and delayed secondary ossification center (arrow, blue stained), in contrast with the red secondary ossification center of their WT
littermates (right). (D) The ossification centers in the carpus of the cKO mice (left) had more blue-stained areas than that of the WT littermates (right).
(E) The skull of the cKO mice (left) had smaller size and delayed suture closure (arrows), when compared with the WT littermates (right), indicating
that the intramembranous ossification was disturbed in the cKO mice. Scale bars: 1 cm in A, 2 mm in E, 1 mm in B–D.
doi:10.1371/journal.pgen.1002708.g004
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change (,1.4 folds) was not statistically significant from the WT
(data not shown).
The shRNA knockdown of FAM20C in vitro leads to
similar changes in the human and mouse osteogenic cell
lines
The bone phenotypes in the Fam20c cKO mice appear opposite
to those observed in the patients associated with the human
FAM20C mutations [6]. These contradictory results raise the
question of whether FAM20C functions differently between the
two species. The lentiviral shRNA-mediated ‘‘knockdown’’ of
FAM20C in mouse preosteoblasts MC3T3-E1 cells, human Saos-
2 cells (osteoblasts isolated from human osteosarcoma) and human
mesenchymal stem cells (hMSC) revealed a remarkable downreg-
ulation of DMP1 (Figure 9A–9C), along with a significant
upregulation of FGF23 in both the human and mouse cell lines
(Figure 9D–9F), indicating that FAM20C may function similarly
in humans and mice.
Recombinant FAM20C promotes cell differentiation in
vitro
To examine the role of FAM20C during osteoblast proliferation
and differentiation, recombinant mouse FAM20C protein was
generated by insect cells using a Bac-to-Bac baculovirus system.
The recombinant FAM20C added to the culture of MC3T3-E1
preosteoblasts promoted the mineral deposition (nodule formation)
in a dose-dependent manner (Figure 10A), and significantly
enhanced the transcription of DMP1, osteocalcin (OCN), and
bone sialoprotein (BSP) (Figure 10B). Adding recombinant
FAM20C to MC3TC-E1 cells did not alter the expression of
FGF23 and the proliferation rate of the cells at all tested
concentrations (data not shown).
Figure 5. Bone defects in the 6-week-old Fam20c-cKO mice revealed by X-ray and histology. (A) Plain X-ray of the hinder legs. The tibia of
the Sox2-Cre-Fam20cD/D (global cKO) mice (left) showed shorter length, hypomineralization, thinner cortical bone (arrow) and underdeveloped
secondary ossification center (arrowhead) compared with their WT littermates (right). The long bones of the Col1a1-Cre-Fam20cD/D (mineralized
tissue-specific cKO) mice (middle image) showed defects very similar to those of the global-cKO mice. (B) Plain X-ray of the tail of Sox2-Cre-Fam20cD/D
mice (left) showed hypomineralization, shorter length, and underdeveloped secondary ossification centers (arrowheads), compared with the WT
littermates (right). (C,D) Micro-CT analyses. The tibia of the Sox2-Cre-Fam20cD/D mice (left) showed shorter length, thinner cortical bone (arrow), more
porous areas on both the outer and inner surfaces (indicating more hypominerlized areas) and smaller secondary ossification centers (arrowheads),
compared with their WT littermates (right). (E) H&E staining of the sagittal sections of tibias. Tibias of the Sox2-Cre-Fam20cD/D mice (left image) and
Col1a1-Cre-Fam20cD/D mice (middle image) were smaller and underdeveloped compared with the WT littermates (right image). (F) Higher
magnification of the metaphysis areas in E showed that the growth plates of the global cKO mice (left image) and mineralized tissue-specific cKO
mice (middle image) had a thinner zone of proliferative chondrocytes (dashed lines) and a wider zone of hypertrophic chondrocytes (solid lines) than
the WT littermates (right image). (G) Higher magnification of the cortical bone areas in E showed that the cortical bone of the global cKO mice (left
image) and mineralized tissue-specific cKO mice (middle image) had more osteoids (grey areas indicated by arrowheads) compared with the WT
littermates (right image). Scale bars: 1 mm in A–D, 200 mm in E, 50 mm in F and G.
doi:10.1371/journal.pgen.1002708.g005
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Inactivation of FAM20C leads to hypophosphatemia and
elevation of serum FGF23
Seeing the significant elevation of FGF23 in the bone cells of
Fam20c cKO mice, we performed serum biochemistry analyses in
18-day- and 42-day-old mice (Table 3). The circulating FGF23
level was remarkably elevated in both the 18-day-old (,200 folds)
and 42-day-old (,60 folds) cKO mice. Accordingly, the serum
phosphorus level significantly decreased at both ages (,2.5 folds in
18-day-old cKO, ,2 folds in the 42-day-old cKO mice). The
circulating PTH level was significantly elevated in both the18-day-
old (,8 folds) and the 42-day-old (,5 folds) cKO mice. The serum
1,25(OH)2D3 level was significantly reduced (,2 folds) in the 18-
day-old cKO mice, while the serum 1,25(OH)2D3 level in the 42-
day-old cKO mice was slightly higher than that of the WT, but the
change in the older mice was not statistically significant. The
serum calcium level slightly decreased in the 18-day- and 42-day-
old cKO mice, but the reduction was not statistically significant
from the WT mice. The blood urea nitrogen (BUN) level in cKO
mice had no statistic difference from that of the WT mice at both
ages, indicating that no renal failure was occurring in the cKO
mice. The serum biochemistry results of the Sox2-Cre-Fam20cD/+
(heterozygous cKO) mice were not different from their WT
literates (data not shown).
The transcriptional levels of renal Klotho and NaPi-2a were
slightly lower in the 18-day-old Fam20c cKO mice, and
significantly downregulated (,3 folds) in the 42-day-old cKO
mice. The renal 1a-hydroxylase level was significantly reduced
(,2 folds) in the cKO mice at both ages. We also observed
remarkable upregulation of renal 24-hydroxylase in the 18-day-old
cKO mice (,30 folds) as well as in the 42-day-old cKO mice (,7
folds) (Table 4). The transcriptional levels of these genes in the
heterozygous Fam20c cKO mice had no difference from their WT
littermates (data not shown).
Expression of the Fam20c transgene rescued the defects
of Sox2-Cre-Fam20cD/D mice
Conditional transgenic (cTg) mice expressing the full length
FAM20C were generated to test the gain of function in vivo. We
obtained 15 lines of cTg mice, and three of them with the
transgene expression levels of 4,8 folds over those of the WT
littermates were further analyzed. One line with the highest
expression level of the transgene (approximately 8 folds over the
WT, Figure 11A) was characterized in detail. No abnormalities
were observed in the bone of any of the cTg mice by postnatal 6
weeks (Figure 11B). In addition, by breeding the cTg mice with the
Fam20c cKO mice, we obtained mice expressing the transgene in
the Fam20c knockout background (designated ‘‘Sox2-Cre-Fam20cD/
D-cTg mice’’). The Sox2-Cre-Fam20cD/D-cTg mice had no abnor-
malities in the skeleton by postnatal six weeks (Figure 11B and
11C), indicating that expressing the transgene fully rescued the
defects of the Fam20c-deficient mice. Additionally, IHC staining
using the anti-FGF23 antibodies showed that the expression of the
Fam20c transgene rescued the altered expression of FGF23 in the
Fam20c-deficient bone (Figure 11D). The fact that overexpressing
FAM20C in the WT background did not cause defects in the
bone, along with the observation that overexpressing the transgene
rescued the Fam20c-deficient abnormalities, has provided further
evidence that the defects in the hard tissues of the Sox2-Cre-
Fam20cD/D mice resulted from the loss-of-function, and were not
due to the gain-of-function.
In summary, the multipronged approaches in this study
demonstrated that inactivation of FAM20C in mice led to
rickets/osteomalacia, along with altered levels of serum phosphate
and FGF23. The manifestations of the Fam20c-deficient mice are
consistent with a diagnosis of hypophosphatemic rickets. The
Fam20c-deficient cells in the mineralized tissues appeared imma-
ture and incapable of forming healthy tissues. It is likely that a
combination of cell differentiation failure and hypophosphatemia
resulting from the FGF23 excess led to the skeletal defects in the
Fam20c-deficient mice.
Discussion
Little is known about FAM20C, a new molecule. In vitro studies
have shown that it promotes the differentiation and mineralization
processes of undifferentiated mesenchymal cells and odontoblasts
[5], whereas human genetic studies suggested that FAM20C might
be a down-regulator (inhibitor) of bone formation and/or
mineralization [6]. To answer critical questions regarding the
biological roles of FAM20C, we generated Fam20c conditional
knockout mice, in which exons 6–9 (majority of the conserved
CCD region) were ablated. It is worth noting that most of the
mutations identified in the patients with lethal osteosclerotic bone
dysplasia were in exons 6–9 [6]. The Fam20c conditional knockout
mice developed hypophosphatemic rickets but not osteosclerosis.
We believe that the abnormalities in the Fam20c cKO mice
resulted from the loss-of-function and were not due to the gain-of-
function for this protein. This belief is based on the following
observations: 1) deleting exons 6–9 (majority of the CCD) in the
Fam20c cKO mice was most likely to inactivate this molecule; 2)
the inheritance of the phenotypic changes in Fam20c cKO mice
occurred in an autosomal recessive trait, while the gain-of-function
is usually inherited in an autosomal dominant manner; 3)
transgenic mice overexpressing the Fam20c transgene were
normal; 4) the overexpression of the Fam20c transgene fully
rescued the phenotypic changes in the Fam20c cKO mice; and 5)
recombinant FAM20C promoted the differentiation and miner-
alization of MC3T3-E1 cells in a dose-dependent manner. These
data combined with a significant downregulation of osteoblast
differentiation markers in cKO mice suggest that FAM20C is
essential to the differentiation of mineralizing cells and promotes
the formation and mineralization of hard tissues, and thus,
inactivation of this molecule leads to differentiation failure of the
cells forming these tissues. Additionally, the Fam20c cKO mice
developed hypophosphatemia with a remarkable elevation of the
serum FGF23 level. We believe that a combination of cell
differentiation failure and hypophosphatemia caused by the
Table 1. Quantitative m-CT analyses of the cortical bone (the
midshaft region) of the tibias from 3-week-old and 6-week-old
WT and Fam20c-cKO mice.
Variables 3-week-old 6-week-old
(Mean ± SD) WT (n=6) cKO (n=6) WT (n=6) cKO (n=6)
BV/TV 0.9160.12 0.7060.05* 0.9660.11 0.9160.12
Apparent density
(mg/cm3)
715612 505616* 924615 708613*
Material density
(mg/cm3)
831613 681615* 1021618 827616*
BV/TV: ratio of bone volume (BV) to total volume (TV); Apparent density:
average mineral density within the segmented area of all voxels thresholded as
bone; Material density: average mineral density of all voxels segmented as bone
including voids;
*: significant difference from WT mice (p,0.05).
doi:10.1371/journal.pgen.1002708.t001
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increase of serum FGF23 led to the skeletal defects in the Fam20c
conditional knockout mice.
In 2007, Simpson et al. reported that the mutations of human
FAM20C are associated with an osteosclerotic phenotype in some
patients [6]. In a later study by the same group [8], Simpson et al.
identified FAM20C mutations in two patients whom they believed
were suffering from a ‘‘different type of Raine Syndrome’’; these
two patients did not show a generalized increase in bone density,
with one case showed ‘‘manifestations consistent with a diagnosis
of hypophosphatemic rickets’’, as the authors stated. The
osteosclerotic phenotype in some patients with FAM20C mutations
appears opposite to that observed in the Fam20c-deficient mice.
These contradictory results raise questions of whether different
domains/fragments of FAM20C protein have different functions
or if their functions are different between humans and mice.
In previous reports, the human FAM20C mutations in the
osteosclerotic patients include point missense mutations and
‘‘splicing’’ mutations [6,8]. The point mutations were located in
different regions of the gene, including the region encoding the N-
terminal portion of the protein and that corresponding to the C-
Figure 6. Reduced mineralization level in the Sox2-Cre-Fam20c-cKOmice. (A) Goldner-Masson trichrome staining of sagittal sections from the
undecalcified tibias of the cKO mice (left) and their WT littermates (right). The cKO mice showed more red staining (unmineralized osteoid) and less
green staining (mineralized bone) compared with the WT. (B) Higher magnification of the cortical bone areas in A showed that the cortical bone of
the cKO mice (upper) had more osteoid (red stained areas indicated by arrowheads), compared to the WT (lower). (C) IHC staining against biglycan on
the sagittal sections of tibias from 3-week-old cKO mice (left) and their WT littermates (right). Note that the cKO mice had more biglycan. (D) Higher
magnification of the cortical bone areas in C showed that the cortical bone of cKO mice (upper) had more biglycan (arrowheads), compared with the
WT (lower). (E) Double fluorescence labeling of the tibia from 6-week-old cKO mice (left) and WT littermates (right). The first injection (calcein)
produced a green label, while the second injection (Alizarin Red) gave rise to a red label. The distance between the green and red labeling indicated
the mineral deposition in the period between the two injections (7 days). The tibia cortical bone of the cKO mice (left) showed narrower distance and
blurry boundary between the two labels compared with the WT (right). (F) The quantitative measurements of the distance between the two
injections revealed a significantly lower mineral deposition rate in the cKO mice compared with their WT littermates. ***P,0.005. Scale bars: 200 mm
in A and C, 50 mm in B, D and E.
doi:10.1371/journal.pgen.1002708.g006
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terminal part. The 1309GRA mutation (D437N, in exon 7)
observed in the ‘‘hypophosphatemic rickets’’-like patient (Case 1 in
[8]) is located between the two missense mutations 1121TRG
(L374R, in exon 6) and 1603CRT (R535W, in exon 10) and was
very close to a splicing mutation C1322-2ARG (in intron 7). The
latter three mutations initially reported by Simpson et al. were
associated with a generalized hypermineralization in the patients
[6], while the former one was associated with ‘‘hypophosphatemic
rickets’’ [8]. The secreted form of mouse FAM20C contains 553
amino acid residues (excluding a putative 26-amino acid signal
peptide), and its calculated molecular mass is approximately
63 kDa. In our previous study [7], Western immunoblotting
analyses of the culture medium from HEK-293 cells transfected
with a pMES construct containing full-length mouse FAM20C
cDNA demonstrated a single protein band at approximately
65 kDa, consistent with the expected mass of full-length mouse
FAM20C. We did not observe any lower molecular weight protein
bands that could be recognized by the anti-FAM20C antibodies.
Similar results were documented in the analyses of the mouse
C3H10T1/2 cells and MC3T3-E1 cells transfected with the
FLAG-tagged FAM20C [5]. These observations indicate that
mouse FAM20C may not be proteolytically processed into
fragments. Taken together, these human and mouse data do not
support the contention that different domains or fragments of
FAM20C may perform different functions.
In this study, the lentiviral shRNA-mediated knockdown of
FAM20C in the human mesenchymal stem cells and human
osteoblasts led to a remarkable downregulation of DMP1, along
with a significant upregulation of FGF23 (Figure 9B, 9C, 9E, and
9F). The findings in the human cells are consistent with the results
in the shRNA-knockdown of FAM20C in mouse MC3T3-E1 cells
(Figure 9A and 9D) and with the observations in the Fam20c
conditional knockout bone (Figure 8, Table 2); these results
indicate that FAM20C is likely to function similarly in humans and
Figure 7. Growth plate defects in the 3-week-old Sox2-Cre-Fam20c-cKOmice. (A) ISH staining of Col II on the sagittal sections of tibia showed
less Col II in the growth plate of cKO mice. The pink/red color indicates positive ISH staining. (B) Higher magnification of the boxed area in A revealed
less Col II in both the proliferative chondrocytes (dashed lines) and hypertrophic chondrocytes (solid lines) in the growth plate of the cKO mice
compared with WT littermates. (C) ISH staining of Col X showed lower expression in the growth plate of the cKO mice. (D) Higher magnification of the
boxed area in C revealed less Col X in the hypertrophic chondrocytes (solid lines) of the cKO mice compared with WT. (E) BrdU staining on the sagittal
sections of tibia. (F) Higher magnification of the boxed area in E revealed fewer proliferating cells in the zone of proliferative chondrocytes (dashed
lines) of the cKO mice compared with WT. (G) TUNEL assay revealed fewer apoptotic cells in the zone of hypertrophic chondrocytes (arrowheads) of
the cKO mice (left) compared with WT littermates (right). Counter stained with DAPI. (H) Statistical counting of apoptotic cells in G showed
significantly less number in the growth plate of the cKO mice. *** P value,0.001. Scale bars: 200 mm in A, C, E and G. 50 mm in B, D and F.
doi:10.1371/journal.pgen.1002708.g007
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mice. Clearly, more studies are warranted to further clarify the
discrepancy between the human and mouse data.
As a growth factor, FGF23 principally functions as a
phosphaturic hormone via binding to the Klotho/FGF receptor
(FGFR) complexes in the kidney [30,31]. The binding of FGF23 to
FGFR accelerates phosphate excretion into the urine, thereby
inducing a negative phosphate balance, which helps maintain the
serum phosphate levels in the normal range under physiological
conditions (Figure 12). Elevation of the FGF23 plasma level is
known to lead to renal phosphate-wasting and hypophosphatemia
[11–15,28,32–35]. The main sources of FGF23 are the osteoblasts
and osteocytes in the skeleton [11,28,29], and a number of studies
have shown that inactivating mutations in certain molecules
expressed by these bone cells increase the plasma level of FGF23,
which leads to hereditary hypophosphatemic rickets [10,11,13,14].
Inactivating mutations in the phosphate-regulating gene with
homologies to endopeptidases on the X chromosome (PHEX)
cause X-linked hypophosphatemic rickets (OMIM 307800) [10],
and loss of DMP1 activity results in autosomal-recessive hypo-
phosphatemic rickets (OMIM 241520) [11,13]. The phenotypic
changes in the Fam20c-conditional knockout mice share many
similarities (hypomineralization, elevation of FGF23, hypophos-
phatemia) with those observed in the PHEX- and DMP1-deficient
subjects. As in the cases of PHEX- and DMP1-deficiency, FGF23
was overexpressed in the bones of the Fam20c cKO mice
(Figure 8K and 8L, Table 2). The overproduction of FGF23 by
the bone cells is likely to be responsible for the elevation of this
protein in the serum.
Mutations in four genes, FGF23 itself, PHEX, DMP1 and
ENPP1, have been reported to remarkably increase the plasma
levels of FGF23, leading to hereditary hypophosphatemic rickets
[9–11,13–15]. Dmp1-, Phex- and Fam20c-deficient mice shared
similarities in osteomalacia, hypophosphatemia and the remark-
able elevation of FGF23 in the circulation and skeleton.
Interestingly, an alteration of Fam20c expression was not observed
in the Dmp1 KO mice or Hyp mice, while remarkable
downregulation of Dmp1 (but not Phex) was observed in the
Fam20c cKO mice. An up-regulation of Dmp1 was observed in
MC3T3-E1 cells treated with recombinant FAM20C. On the
other hand, a remarkable down-regulation of Dmp1 was seen in
human and mouse osteogenic cell lines treated with FAM20C-
shRNA. These findings, along with the similarities of skeletal and
serum changes between the Fam20c-deficient and Dmp1-deficient
mice, raise the question of whether FAM20C regulates DMP1
(Figure 12). Clearly, further studies are warranted to answer this
question. Additionally, there are still a pool of patients with
hereditary hypophosphatemic rickets whose etiology is unknown
[35,36], and our discovery that the inactivation of Fam20c in mice
results in hypophosphatemic rickets necessitates a consideration of
screening FAM20C in such patients.
High level FGF23 reduces the expression of renal vitamin D 1a-
hydroxylase and increases the expression of the catabolic 25-
hydroxyvitamin D 24-hydroxylase, thus leading to decreased levels
of 1,25(OH)2D3 in the serum [15,37,38]. In the 18-day-old Fam20c
cKO mice, the 1,25(OH)2D3 level was significantly lower, while in
the 42-day-old cKO mice the 1,25(OH)2D3 level managed to
return to the normal range (or a not significantly higher level).
Similar shifts in the serum 1,25(OH)2D3 level with aging have
been observed in other hypophosphatemic models such as the
Fgf23 transgenic mice, Hyp mice and Dmp1-KO mice that have
high levels of circulating FGF23 [11,12,39].
While elevation of serum FGF23 reduces the expression of the
renal 1a-hydroxylase, hypophosphatemia is normally a stimulator
for renal 1a-hydroxylase expression to increase circulating
1,25(OH)2D3 [40]; the stimulating effect of hypophosphatemia
on the 1a-hydroxylase expression has been well illustrated in the
NaPi2a knockout mice (with lower phosphate and lower FGF23
levels in the serum), in which the serum 1,25(OH)2D3 level is
elevated due to the increased 1a-hydroxylase expression stimulat-
ed by hypophosphatemia [41]. The Fam20c-cKO mice displayed a
decreased level of renal 1a-hydroxylase in the presence of
hypophosphatemia, indicating that in these mutant mice, the
negative modulation of FGF23 on the expression of the 1a-
hydroxylase may outweigh the stimulating effect of hypophospha-
temia on the 1a-hydroxylase expression.
In comparison with the Fgf23 transgenic mice, Dmp1-KO mice
and Hyp mice, a more remarkable upregulation of 24-hydrox-
ylase was observed in the kidney of the Fam20c-cKO mice, which
may be due to the fact that Fam20c-cKO mice have a higher
serum FGF23 level than the former three [11,12,33]. A higher
level of 24-hydroxylase in the 18-day-old cKO mice than that in
the 42-day-old Fam20c cKO mice (,30-fold versus ,7-fold
elevation) may be responsible for the significantly lower serum
1,25(OH)2D3 level in the younger animals. In the older Fam20c
cKO mice, a significant reduction of FGF23 co-receptor Klotho,
along with a relatively lower serum FGF23 level than that in the
younger cKO mice, may attenuate the FGF23-elevation effects
on circulating 1,25(OH)2D3 and thus may help maintain a
Table 2. Alterations of selected genes in the calvaria of 3-week-old Fam20c-cKO mice.
Gene symbol Microarray (n =1) Q-PCR (n =6) Known function*
Fgf23 5.4 112632.9 Regulator of phosphate homeostasis9–15
Fst 3.4 6.661.2 Antagonist of TGF-b/Activin pathway19,20
Sfrp1 3.4 1.860.4 Inhibitor of canonical Wnt pathway21
Sfrp3 3.0 1.660.5 Inhibitor of canonical Wnt pathway22
Lgr5 23.6 27.760.9 Downstream target of Wnt Pathway23,24
Lef1 21.9 23.260.4 Downstream target of Wnt Pathway25
Dmp1 21.7 22.360.6 Promoter of osteoblast maturation11
Ocn NA 29.360.8 Regulator of biomineralization26
Osterix NA 21.960.6 Promoter of osteoblast differentiation27
The mRNA levels in the Fam20c-cKO mouse calvaria were expressed as folds of change over their WT littermates.
*For the known functions of each gene, please refer to the references in superscripts.
doi:10.1371/journal.pgen.1002708.t002
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relatively normal serum 1,25(OH)2D3 level in the older cKO
mice. More likely, the lower serum level of 1,25(OH)2D3 in the
younger Fam20c KO mice may have triggered the overproduction
of PTH, as in the cases of Fgf23 transgenic mice and Hyp mice.
The secondary hyperparathyroidism may play a critical role for
reversing the 1,25(OH)2D3 level to the normal range in the older
Fam20c cKO mice [42,43]. In addition, the elevated PTH may
synergize with the high level of serum FGF23 to increase renal
phosphate excretion by reducing the expression of NaPi2a in the
proximal tubules [38,44]; a significant reduction of NaPi2a was
observed in the kidney of the Fam20c cKO mice. In the end,
1,25(OH)2D3 may maintain a relatively normal level in the older
Fam20c cKO mice at the expense of a significant phosphorus
wasting.
The skeletal defects of the PHEX- and DMP1-deficient subjects
are believed to be due to the combined effects of two factors: 1) the
intrinsic defects of the PHEX- and DMP1-deficient cells that
prevent them from forming and mineralizing ECM properly and
2) hypophosphatemia [11,33,45,46]. The Fam20c-deficient cells
responsible for forming the mineralized tissues appeared immature
and showed altered expression levels for molecules associated with
cell differentiation. While hypophosphatemia in the Fam20c
conditional knockout mice can be attributed to the overproduction
of FGF23 in the abnormal skeleton, the direct cause of cell
differentiation failure may be complicated. As stated above, the
defects in the mineralized tissues of the Fam20c conditional
knockout mice could be the combined results of cell differentiation
failure and hypophosphatemia. Although the way FAM20C
Figure 8. FAM20C is essential to the differentiation of bone cells. (A,B) SEM analyses of tibia from 6-week-old Sox2-Cre-Fam20c-cKO mice
(upper) and WT littermates (lower). The osteocytes of the cKO mice showed abnormal shape (green arrows), wider periosteocytic region (red asterisk),
and loss of osteocyte processes (red arrowheads), appearing immature and poorly differentiated. (C,D) Backscatter SEM analyses of the alveolar bone
showed that the osteocytes in the 6-week-old Sox2-Cre-Fam20c-cKO mice (upper) had periosteocytic lesions (the ‘‘halo’’ defects, i.e., wider
unmineralized regions surrounding the ostecytes) appearing as larger lacunae (arrows) compared with their WT littermates (lower). The black areas
represent the unmineralized areas (osteocytes, periosteocytic region, osteocyte processes), while the grey/white areas represent the matrix that is
well mineralized. (E–J) ISH staining of Col1a1, OCN, and DMP1 on the sagittal sections of tibia from 3-week-old cKO mice (upper panels) and WT
littermates (lower panels), revealed significant downregulation of these terminal differentiation markers in the cKO mice. The pink/red color
represents the positive ISH staining. (K) IHC staining of FGF23 in the tibia from 3-week-old cKO mice and their WT littermates revealed more FGF23
protein in the long bone of the cKO (left) than in the WT (right) mice. The brown color represents the positive IHC staining. (L) Higher magnification of
the box areas in K showed more FGF23 protein in the osteocytes (arrowheads) and the bone matrices (arrows) of the cKO mice (upper) than in the WT
(lower). Scale bars: 5 mm in A and B, 10 mm in C and D, 50 mm in L, 200 mm in E–K.
doi:10.1371/journal.pgen.1002708.g008
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regulates cell differentiation has not yet been defined in this study,
our data suggest that FAM20C may regulate the differentiation
and function of the mineralizing cells by participating in certain
signaling pathways.
Several lines of evidence suggested that FAM20C might be
associated with the canonical Wnt signaling pathway. The Wnt
canonical pathway inhibitors, secreted frizzled related protein 1
(Sfrp1) and Sfrp3, were upregulated in the Fam20c-deficient mice.
Accordingly, the downstream target genes of Wnt pathway,
leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5)
and lymphoid enhancer-binding factor 1 (Lef1) were significantly
downregulated in the Fam20c-deficient bone. Lgr5 is a stem cell
marker and a Wnt pathway regulator which has been identified in
multiple tissues including bone marrow cells [23,24]. Lef1 is a
Wnt-responsive transcription factor that associates with b-catenin
and has been documented to increase osteoblast activity and
Figure 9. Lentiviral shRNA-mediated ‘‘knockdown’’ of FAM20C leads to similar alterations in the expression of DMP1 and FGF23 in
human and mouse osteogenic cell lines. The cells were divided into three groups: uninfected cells, cells infected with control lentivirus
expressing the scrambled shRNA and cells infected with FAM20C-shRNA lentivirus containing a mixture of 3 pieces of shRNA targeting different
regions of the FAM20C mRNA. The mRNA levels of DMP1 and FGF23 in each group were determined by real-time PCR. The expression levels of the
uninfected cells without osteogenic induction were taken as 1, while that of the cells infected with the control virus or FAM20C-shRNA virus were
expressed as folds of change to the uninfected cells. (A) The knockdown of FAM20C led to remarkable downregulation of DMP1 in mouse MC3T3-E1
cells. Without the osteogenic induction, the expressional level of DMP1 had no significant difference among the three groups of cells. During the 3-
week osteogenesis-induction process, DMP1 was significantly upregulated in the uninfected cells and cells infected with the control lentivirus, while
its expression was remarkably reduced in the cells infected with FAM20C-shRNA lentivirus at 1-, 2- and 3-weeks after the start of osteogenic
induction. (B) Inactivation of FAM20C led to remarkable downregulation of DMP1 in hMSC cells. The expression level of DMP1 had no significant
difference among three groups in the first 2 weeks of culture in the osteogenic medium. After 3 weeks of osteogenic induction, the DMP1 expression
was remarkably reduced in the cells infected with FAM20C-shRNA lentivirus when compared with the uninfected cells and cells infected with the
control lentivirus. (C) Inactivation of FAM20C led to remarkable downregulation of DMP1 in Saos-2 cells. DMP1 expression was downregulated in
human osteoblasts (Saos-2) infected with FAM20C-shRNA lentivirus before the osteogenic induction started, compared with the uninfected cells and
cells infected with the control virus. The downregulation of DMP1 in the FAM20C-knockdown cells became more prominent after 1 week of
osteogenic induction. (D) Inactivation of FAM20C led to significant upregulation of FGF23 in mouse MC3T3-E1 cells. The expression level of FGF23
had no significant difference among three groups in the first 2 weeks of osteogenic induction. After inducing the cells for osteogenic differentiation
for 3 weeks, FGF23 was significantly upregulated in the cells infected with FAM20C-shRNA lentivirus, compared with the uninfected cells and cells
infected with the control lentivirus. (E) Inactivation of FAM20C led to significant upregulation of FGF23 in hMSC cells. The FGF23 elevation also
occurred in the hMSC cells after 3-week osteogenic induction. Note that upregulation of FGF23 in the hMSC cells was not as remarkable as in the
MC3T3-E1 cells at the same time point. (F) Inactivation of FAM20C led to significant upregulation of FGF23 in Saos-2 cells. Without osteogenic
induction, FGF23 level had no significant difference among the 3 groups. After 1 week of osteogenic induction, FGF23 was significantly upregulated
in the cells infected with FAM20C-shRNA lentivirus, compared with the uninfected cells and cells infected with the control lentivirus. *: P,0.05; **:
P,0.01; NI: without osteogenic induction; Control: uninfected control cells; Control virus: cells infected with control lentivirus; FAM20C-shRNA virus:
cells infected with FAM20C-shRNA lentivirus.
doi:10.1371/journal.pgen.1002708.g009
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trabecular bone mass [25]. However, not all of the findings
support the postulation that FAM20C is a participant in the Wnt
signaling pathway. For example, the level of axis inhibition protein
2 (Axin2), a putative Wnt downstream target gene, was unchanged
in the Fam20c-deficient bone. In addition to the molecules in the
Wnt signaling pathway, Follistatin (Fst), a potent inhibitor of
Activin and the TGF-b pathway, was significantly upregulated in
the bones of 3-week and 6-week-old Fam20c-deficient mice. Fst has
been reported to inhibit ameloblast and osteoblast differentiation
[19,20], suggesting a possible association between FAM20C and
the TGF-b pathway.
Type II and Type X collagen were downregulated in the growth
plates of the Fam20c conditional knockout mice. The downregu-
lation of these genes may arise from the intrinsic defects of
chondrocytes or occur as a systematic consequence of hypophos-
phatemia. It has been well documented that hypophosphatemia
significantly decreases programmed cell death in growth plates by
impairing caspase-mediated apoptosis of hypertrophic chondro-
cytes [17,18].
In conclusion, the results in this investigation have demonstrat-
ed the crucial role of FAM20C in osteogenesis. Our findings
indicate that FAM20C is essential to the differentiation of
osteoblasts/osteocytes and is involved in the regulation of
phosphate homeostasis via the mediation of FGF23.
Methods
Ethics statement
All animal procedures were performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals and approved by
the Institutional Animal Care and Use Committee of Texas A&M
Health Science Center, Baylor College of Dentistry (Dallas, TX,
USA).
Generation of Fam20c conditional knockout mice lacking
exons 6,9
To generate the Fam20c conditional knockout mice, a 2.2 kb
targeting fragment spanning exons 6,9 of mouse Fam20c was
produced by PCR using the genomic DNA of WW6 ES cells as a
template (forward primer: 59-CTCTCGGGTGAGGCTGTAAG-
39; reverse primer: 59-AGATCTCTTAGGGAAGAGGGGT-
CAGG-39). The fragment was subcloned into a floxed BamHI
Figure 10. Recombinant FAM20C promotes the differentiation of MC3T3-E1 cells. (A) Alizarin red was used to stain the mineralized
nodules formed by MC3T3-E1 cells treated with different concentration of recombinant FAM20C. The lower panel showed the representative culture
wells from each of the experimental groups as well as the control group. The upper graph displayed the quantitative measurement of Alizarin red dye
released from the mineralized nodules formed by MC3T3-E1 cells. Note that the administration of FAM20C improved the mineralized nodule
formation in a dose-dependent manner. (B) Real-time PCR using RNA extracted from MC3T3-E1 cells treated with recombinant FAM20C (800 ng/ml)
revealed upregulation of DMP1, OCN and BSP in the experimental groups. *: P value,0.05; **: P value,0.01; ***: P value,0.001.
doi:10.1371/journal.pgen.1002708.g010
Table 3. Serum biochemistry results in the 18-day-old and 42-day-old WT and Fam20c-cKO mice.
Serum biochemistry 18-day-old 42-day-old
(mean ± SD) WT (n=6) cKO (n=6) WT (n=6) cKO (n=6)
FGF23 (pg/ml) 223.7637.0 46771.2611687.1** 226.3690.8 13631.562585.0**
Phosphorus (mg/dl) 15.4863.05 6.3161.46 ** 11.1061.38 5.6260.61**
Intact PTH (pg/ml) 132.56114.0 1076.96356.8** 52.3616.8 302.6673.1**
1,25(OH)2D3 (pmol/L) 260.3625.1 148.3621.9** 120.2655.3 172.8647.2
Calcium (mg/dl) 8.2860.36 7.6261.72 9.7561.10 8.0261.43
BUN (mg/dl) 9.162.3 8.662.7 16.163.6 17.264.3
A p-value of ,0.05 was taken as statistically significant difference.
**: significant difference from the WT mice (p,0.001). BUN: blood urea nitrogen.
doi:10.1371/journal.pgen.1002708.t003
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site upstream of an Frt flanked mcl-Neo cassette in the conditional
targeting vector pFlox-Frt-Neo [47]. A 2.5 kb 59 homologous arm
was generated by PCR (forward primer: 59-CTCGAGTGGGT-
GTGTCAGGAATCGTA-39; reverse primer: 59-CTCGAGACC-
CGAGAGCAACCACATAC-39), and subcloned into the XhoI
site of the targeting vector. A 4.2 kb 39 homologous arm with EagI
sites at both ends was generated by PCR (forward: 59-TCGG-
CCGTTGGACATAGGCTCCCAAAG-39; reverse: 59-TGTG-
CAGGATTGAGAACCAG-39), and subcloned into the NotI site
of the targeting vector. Finally, a negative selection PGK-DTA
(diphtheria toxin A) cassette was subcloned into the NotI site
downstream of the 39 homologous arm in the targeting vector
(Figure 1A). The final targeting construct was linearized with SacII
and electroporated into W4 ES cells (Transgenic Mouse Core
Facilities, University at Albany, Rensselaer, NY, USA). Clones
were picked after G418 selection. Genomic DNA was extracted
from the ES cells in duplicate plates, and PCR analyses were per-
formed to screen the targeted clones (59 screen primers: 59S-F: 59-
TTTCTGTCCTAGGTAAGGGTGAAG-39, 59S-R: 59-
ACTGCTCGATGAAGTTCCTATTCT-39; 39 screen primers:
39S-F: 59-TGTTCGGATCGAAGTTCCTATACT-39, 39S-R: 59-
ACAGCTTCTTGAATTGGGATAAAG-39) (Figure 1A and 1B).
The 59 and 39 screening PCR products were sequenced to confirm
the correct targeting and the presence of 59 and 39 loxP sites.
Two correctly targeted ES cell clones (Clone 286 and 297,
Figure 1B) were identified. The neo cassette was removed from the
targeted ES clones by transient transfection of pCAGGS-flpE-
puro vector (Addgene plasmid 20733) [48]. The removal of the
neo cassette was confirmed by PCR (forward: 59-GCATCTGCA-
GACCGAGCCCA-39, reverse: 59-CCCCCTGTCCTGAGGG-
CTGA-39). Random integration of pCAGGS-flpE-puro DNA into
ES cell genome was excluded by PCR analyses (forward: 59-
GCATGGCCGAGTTGAGCGGT-39, reverse: 59-GGTGAC-
GGTGAAGCCGAGCC-39). The targeted ES clones recovered
from the master plates were injected into the blastocysts of
C57BL/6 mice in the Transgenic Core Facility of the University of
Texas Southwestern Medical Center at Dallas. Male chimeras
were crossbred with C57BL/6 females to produce F1 agouti
offspring. The floxed alleles of F1 agouti mice were genotyped by
PCR analyses (see below). To generate Fam20c conditional
knockout mice, the F1 heterozygous mice (Fam20cflox/+) were first
crossbred with Sox2 promoter-driven Cre transgenic mice
(Jackson Laboratory) that express the Cre recombinase transgene
in the epiblasts at E6.5; this breeding gave rise to Sox2-Cre-
Fam20cD/+ mice in which exons 6,9 were removed from one
allele of the Fam20c gene. The Sox2-Cre-Fam20cD/+ mice were
inbred to produce Fam20c conditional knockout (cKO) mice
designated as ‘‘Sox2-Cre-Fam20cD/D mice’’, in which exons 6,9
were removed from both alleles of the Fam20c gene.
Genotypes were determined by PCR analyses using genomic
DNA extracted from the mouse tails. The floxed allele was
distinguished from the wild type (WT) allele by PCR analyses
using a mixture of three primers (a: 59-TCCAGCTTGCTAGG-
GCTCTGACC-39, b: 59-CTATGTCCAACGGCCGCAGCTT-
39, and c: 59-GTCCTGAGGGCTGACCCAAGACTA-39)
(Figure 1A and 1C). The null allele (i.e., that with exons 6,9
removed) arising from Cre-loxP recombination events was
detected by PCR using primers Rec-F: 59-GTGGTCT-
CTGCCGCTGATGTACC-39 and Rec-R: 59-TTTGGGAGCC-
TATGTCCAACGGCC-39 (Figure 1A and 1C). Genotyping for
the Cre transgene was determined by PCR using primers Cre-F:
59-CCCGCAGAACCTGAAGATG-39 and Cre-R: 59-GACC-
CGGCAAAACAGGTAG-39.
We also used the 3.6 kb Col 1a1 promoter-Cre transgenic mice
(The Jackson Laboratory) to generate ‘‘Col1a1-Cre-Fam20cD/D
mice’’, in which FAM20C was inactivated in tissues expressing
type I collagen. We first crossbred the Fam20cflox/+ mice with
3.6 kb Col 1a1 -Cre mice, and then inbred the offspring of the
Col1a1-Cre-Fam20cD/+ mice to get Col1a1-Cre-Fam20cD/D mice.
Generation of Fam20c conditional transgenic mice and
mice expressing the transgene in the Fam20c conditional
knockout background
To generate Fam20c conditional transgenic mice, the coding
sequence of mouse Fam20c cDNA was subcloned into a bicistronic
pMES vector [49] downstream to a chicken b-actin promoter and
upstream to an IRES-EGFP cassette as previously described [7]. A
floxed STOP cassette was inserted between the b-actin promoter
and the Fam20c sequence to block the transcription of the
transgene. The Fam20c transgene can be activated only after the
floxed STOP cassette is removed by Cre recombinase [7]. This
Fam20c conditional transgenic construct was linearized and
injected into the pronuclei of fertilized eggs from the C57BL/6
mice in the Transgenic Core Facility of the University of Texas
Southwestern Medical Center at Dallas. Fifteen lines of transgenic
mice with the conditional Fam20c transgene were identified by
PCR genotyping using primers located in the exogenous EGFP
sequences (GFP-forward: 59-ACGTAAACGGCCACAAGTTC-
39 and GFP reverse: 59-TGCTCAGGTAGTGGTTGTCG -39).
The mice carrying the conditional transgene were crossbred with
the Sox2-Cre transgenic mice to remove the floxed STOP cassette
between the chicken b-actin promoter and the Fam20c cDNA,
thereby allowing the Fam20c transgene to be transcribed. These
conditional transgenic mice (cTg mice) were genotyped using the
aforementioned GFP primers and Cre primers. The expression
level of the Fam20c transgene in the long bones of each line was
evaluated by quantitative real-time PCR. Three lines with the
transgene expression levels of 4,8 folds over that of the WT mice
were further analyzed.
To generate mice expressing the transgene in the Fam20c
conditional knockout background, we crossbred Sox2-Cre-
Fam20cD/+ mice with cTg mice expressing the highest level of
the trangene to obtain Sox2-Cre–Fam20cD/+-cTg mice, which were
then inbred to produce mice expressing the transgene in the
Fam20c conditional knockout background (designated ‘‘Sox2-Cre-
Fam20cD/D-cTg mice’’). PCR analyses with primers used in the
identification of the Fam20c conditional knockout mice and cTg
Table 4. Renal mRNA levels of Klotho, NaPi-2a, 1a-
hydroxylase, and 24-hydroxylase in the 18-day-old and 42-
day-old WT and Fam20c-cKO mice.
Renal mRNA
levels (folds) 18-day-old 42-day-old
(Mean ± SD) WT (n=6) cKO (n=6) WT (n=6) cKO (n=6)
Klotho 1 0.8660.03* 1 0.2860.03**
NaPi-2a 1 0.8460.03* 1 0.3560.05**
1a-hydroxylase 1 0.5360.03** 1 0.6360.07**
24-hydroxylase 1 30.3361.83** 1 6.8760.77**
The renal mRNA level of WT revealed by real-time PCR was taken as 1, while
that of the FAM20C-deficient kidney was expressed as folds of change to the
WT.
*: significant difference from WT mice (p,0.05).
**: significant difference from WT mice (p,0.001).
doi:10.1371/journal.pgen.1002708.t004
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Figure 11. Expression of the Fam20c transgene rescued the defects of Sox2-Cre-Fam20c-cKO mice. (A) The expression level of the Fam20c
transgene was evaluated by real-time PCR using mRNA extracted from the long bones of 6-week-old mice. One line of the transgenic mice (cTg) with
the highest expression level of the Fam20c transgene (,8 folds over that of their WT littermates) was used to rescue the defects in the cKO mice. (B)
Plain X-ray analyses of tibias from 6-week-old mice. The bone of mice expressing the Fam20c transgene in the wild type background (cTg) had no
difference from the WT. Note the tibia of the cKO mice expressing the Fam20c transgene (cTg+cKO) had no difference from the WT, indicating that
the expression of the transgene fully rescued the bone defects of Sox2-Cre-Fam20c-cKO mice (cKO). (C) H&E staining on the sagittal sections of tibias
from 6-week-old WT, cTg, cKO and cTg+cKO mice. The tibia cortical bone of the cKO mice had more osteoids (grey areas indicated by arrowheads)
and thinner cortical bone, while the cortical bones of the WT, cTg and cTg+cKO mice showed normal structures. These findings further demonstrate
that expressing the Fam20c transgene completely rescued the bone defects of the Fam20c cKO mice. (D) Anti-FGF23 IHC staining on the sagittal
sections of tibias in the 3-week-old WT, cTg, cKO and cTg+cKO mice. The cortical bone of tibias in the WT, cTg and cTg+cKO mice showed very similar
level of FGF23 expression while that of the cKO mice demonstrated a significantly elevated FGF23 expression. These results indicate that expressing
the Fam20c transgene rescued the altered FGF23 expression in the cKO mouse bone. Scale bars: 100 mm in C and D.
doi:10.1371/journal.pgen.1002708.g011
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mice were employed in the genotyping of the Sox2-Cre-Fam20cD/D-
cTg mice.
All mice in this study were fed with Teklad 6% fat mouse/rat
diet (Harlan, IN) and some of the chow contents are as follows:
Calcium 2.4%, phosphorus 1.5%, vitamin D 3.0 IU/g.
RT–PCR
Femurs from the Fam20c conditional knockout mice, Sox2-Cre-
Fam20cD/D-cTg mice and the WT littermates were dissected, and
total RNA was extracted using an Rneasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. The total RNAs were
converted into cDNAs using a Reverse Transcription Kit
(Qiagen). RT-PCR was performed to examine the lack of Fam20c
mRNA in the cKO mice using two sets of primers: Set 1-F: 59-
TGCGGAGATCGCTGCCTTCC-39, Set 1-R: 59-GCCACT-
GTCGTAGGGTGGCG-39; Set 2-F: 59-GAGAGCAGGAGAC-
GCCGCCT-39, and Set 2-R: 59-CCACCACACTGCTCAG-
CCCG -39 (Figure 2A).
Alizarin Red/Alcian Blue staining of the skeleton
One-week-old Sox2-Cre-Fam20cD/D mice and WT littermates
were skinned, eviscerated and fixed in 95% ethanol. Alizarin Red/
Alcian Blue staining of the skeletons was performed to visualize the
skeleton and the overall mineralization levels, as described
previously [50].
X-ray radiography
The narcotized mice or the dissected jaws and long bones from
hind legs were analyzed using X-ray radiography (Faxitron MX-
20DC12). Micro-computed tomography (Micro-CT) analyses
were performed using a Scanco micro-CT35 imaging system
(Scanco Medical) with a medium-resolution scan (7.0 mm slice
increment) on the dissected tissues, as previously reported [51].
The images were reconstructed with the EVS Beam software using
a global threshold at 240 Hounsfield units.
Preparation of decalcified sections and H&E staining
Tibia and jaw tissues dissected from the mice were fixed with
4% paraformaldehyde in 0.1% diethyl pyrocarbonate (DEPC)-
treated PBS solution at 4uC overnight and then were decalcified in
0.1% DEPC-treated 15% EDTA (pH 7.4) at 4uC for 8 days. The
tissues were processed for paraffin embedding, and serial 5 mm
sections were prepared for histological analyses. H&E staining was
performed as previously described [17].
Cell proliferation and TUNEL assays
BrdU was administrated to 3-week-old Sox2-Cre-Fam20cD/D
mice and WT littermates at a dosage of 1 ml per 100 g body
weight by intraperitoneal (i.p.) injection according to the
manufacturer’s instructions (Invitrogen). Two hr after the injec-
tion, the mice were sacrificed. Tibias were dissected and processed
for paraffin embedding, and 5 mm sections were prepared for
BrdU detection using a Zymed BrdU staining kit (Invitrogen)
following the manufacturer’s instructions. Apoptosis in growth
plates was examined by TUNEL assay using the ApopTag Plus
Fluorescein In Situ Apoptosis Detection Kit (Millipore) according
to the manufacturer’s instructions. Six serial sections from each of
six individual samples of Sox2-Cre-Fam20cD/D mice and WT
littermates were counted, and the data were analyzed statistically.
Immunohistochemistry (IHC) staining
The IHC experiments were carried out using an ABC kit and a
DAB kit (Vector Laboratories) according to the manufacturer’s
instructions. A polyclonal C-terminal anti-FAM20C antibody was
used at a concentration of 1 mg IgG/ml for the IHC experiments, as
previously described [7]. A monoclonal FGF23 antibody (Cell
Figure 12. FAM20C may mediate phosphate homeostasis via FGF23. FAM20C, DMP1 and PHEX may share similar mechanisms in their
involvement in the bone-kidney axis when regulating phosphate homeostasis via FGF23. FAM20C secreted by osteoblasts/osteocytes may regulate
the phosphaturic hormone FGF23 expression in these cells. FGF23 targets the Klotho/FGF receptor (FGFR) complexes in the kidney, reducing the
expression of the renal sodium-phosphate cotransporters NaPi-2a/2c in the proximal tubules, thereby accelerates phosphate excretion into the urine
and helps maintaining the serum phosphate levels in the normal range. While inactivation of FAM20C led to remarkable reduction of DMP1 in the
mice and osteogenic cell lines, and recombinant FAM20C significantly increased the expression of DMP1 in MC3T3-E1 cells, it is unclear if FAM20C
regulates FGF23 and phosphate homeostasis via DMP1 (dotted arrow) or FAM20C directly regulates FGF23 (dashed line).
doi:10.1371/journal.pgen.1002708.g012
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Essentials) was used at a dilution of 1:400 following the manufac-
turer’s instruction. A polyclonal biglycan antibody (LF-159) was
kindly provided by Dr. Larry Fisher (NIDCR, National Institutes of
Health) [52]. Methyl green was used for counterstaining.
In situ hybridization (ISH)
A 380 bp fragment from the region of exons 6–9 of Fam20c
cDNA was obtained by PCR using forward primer 59-
CCGAGCATGCCCTGTGTGGG -39 and reverse primer 59-
TGCAGCACTGATGAAGAGGAGCG -39. The PCR product
was subcloned into the pCRII-TOPO vector (Invitrogen) and then
linearized with EcoRV to synthesize the antisense RNA probes
using the Sp6 RNA polymerase or with HindIII to synthesize the
sense RNA probes using the T7 RNA polymerase. The constructs
used to generate RNA probes for DMP1, osteocalcin, collagen
type I, collagen type II, and collagen type X were provided by the
laboratory of Dr. Jian Q. Feng. The constructs were linearized and
labeled with digoxigenin (DIG) using a RNA Labeling Kit (Roche,
Indianapolis, IN) as previously described [7]. DIG-labeled RNA
probes were detected by an enzyme-linked immunoassay with a
specific anti-DIG-AP antibody conjugate (Roche) and an im-
proved substrate (Vector Laboratories), which produces a red
color for positive signals, according to the manufacturer’s
instructions. Methyl green was used for counterstaining.
Preparation of undecalcified histology sections
Tibias dissected from 6-week-old mice were fixed in 4%
paraformaldehyde overnight. The specimens were dehydrated
through a graded series of ethanol (70–100%) and embedded in
methylmethacrylate (MMA) without prior decalcification, as
previously described [53]. Ten mm sections were prepared for
Goldner staining and double-labeling fluorescent analysis.
Double fluorochrome labeling
Double fluorescence labeling was performed as previously
described [54]. Briefly, calcein (5 mg/kg i.p.; Sigma-Aldrich) was
administered to the 5-week-old mice, followed by injection of an
Alizarin Red label (20 mg/kg i.p.; Sigma-Aldrich) 7 days later.
The mice were sacrificed 48 hr after the injection of the second
label and the tibias were embedded in MMA; 10 mm sections were
then prepared. The unstained sections were viewed under
epifluorescent illumination using a Nikon E800 microscope,
interfaced with Osteomeasure histomorphometry software (version
4.1, Atlanta, GA). The mean distance between the two fluorescent
labels was determined and divided by the number of days between
labels to calculate the mineral deposition rate (mm/day).
Goldner’s Masson Trichrome staining
Ten mm undecalcified sagittal sections from the tibias were
stained using Goldner-Masson trichrome assay, as previously
described [55]. The cortical bone areas in the midshaft were
photographed using a Nikon microscope at 106 with Bioquant
OSTEO v.7.20.10 (R&M Biometrics) software. Unmineralized
osteoid stains red, and mineralized bone stains green/blue.
Resin-casted scanning electron microscopy (SEM) and
backscattered SEM
For resin-casted osteocyte lacunocanalicular SEM, the surface of
the MMA embedded tibia was polished, acid-etched with 37%
phosphoric acid for 2–10 s, washed with 5% sodium hypochlorite
for 5 min and then coated with gold and palladium and examined
by FEI/Philips XL30 Field emission environmental SEM. Back-
scattered SEM was performed as we previously described [56]
Quantitative real-time PCR and microarray analyses
Total RNAs were isolated from the calvaria bones and
decapsulated kidneys of 3-week-old mice and cultured cells. The
kits for RNA extraction and reverse transcription were the same as
in the RT-PCR experiments. Quantitative real-time PCR was
performed on a Bio-Rad CFX96 system (Bio-Rad) using SYBR
Green Master Mix (Stratagene). The Ct values were normalized to
the reference gene 18s rRNA (SABiosciences), and then expressed
as fold changes compared with the experimental controls. The
primers for human 18s rRNA, mouse 18s rRNA, mouse Fam20c
(NM_030565) and human FGF23 (NM_020638) were bought
from SABiosciences. All other primers were synthesized by
Integrated DNA Technologies (Table S1).
Microarray analyses were performed in the Microarray Core
Facility of University of Texas Southwestern Medical Center at
Dallas, using total RNA extracted from the calvaria of 3-week-old
mice. GeneChip Mouse Genome 430 2.0 Array (Affymetrix) was
employed in the microarray analyses, following the manufacturer’s
instructions. Data analyses were performed using GeneSpring
software (Agilent Technologies). The microarray results were
uploaded to MAGE-TAB ArrayExpress database (accession
number E-MTAB-772).
Serum biochemistry
Serum phosphorus was measured using the phosphomolybdate-
ascorbic acid method, as previously described [57]. Serum calcium
was measured using a colorimetric calcium kit (Stanbio Labora-
tory). The serum FGF23 and PTH levels were measured using a
full-length FGF23 ELISA kit (Kainos Laboratories) and a mouse
intact PTH ELISA kit (Immutopics). Serum 1,25(OH)2D3 was
measured using a 1,25 Dihydroxy Vitamin D EIA Kit (Immuno-
diagnostic Systems). Blood urea nitrogen (BUN) was measured
using a BUN Reagent Kit (BQ Kits).
Generation of recombinant mouse FAM20C
The recombinant mouse FAM20C was expressed by insect cells
using a Bac-to-Bac baculovirus expression system (Invitrogen).
Briefly, the N-terminal of mouse FAM20C (signal peptide
removed) was fused with a baculovirus signal sequence gp67
(envelope glycoprotein), 6xHis (tag), SUMOstar (Small Ubiquitin-
like Modifier), and a TEV (Tobacco Etch Virus) cleavage site. The
fusion gene was inserted into the pFastDual vector (Invitrogen)
downstream of a polyhedrin promoter, and a GFP cDNA was
inserted downstream of a P10 promoter serving as a baculovirus
indicator. The construct was transformed into DH10Bac E. Coli
cells (Invitrogen), in which the fusion gene was introduced into
BacMid via homologous recombination. The BacMid was
extracted from DH10Bac E. Coli cells and transfected into Sf21
insect cells (Invitrogen) to produce the baculovirus. The insect cells
infected with the baculovirus secreted the recombinant FAM20C
into the SFX-insect cell culture medium (Hyclone). After two
rounds of scale-up, the cell culture medium was collected and
subjected to a one-step Ni-NTA purification. Turbo-TEV (Eton
Bioscience) was used to release mouse FAM20C from the fusion
protein, and reverse Ni-NTA purification was performed to
remove Turbo-TEV, His tag, and SUMOstar.
Cell culture and in vitro gain- and loss-of-function
analyses
Mouse MC3T3-E1 cells were grown in a-MEM medium
(Gibco) supplemented with 10% fetal bovine serum (Hyclone) and
antibiotics (Gibco); human Saos-2 cells (ATCC, osteoblasts from
human osteosarcoma) were grown in McCoy’s 5a medium (Gibco)
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supplemented with 15% fetal bovine serum; human mesenchymal
stem cells (hMSC) (Lonza) were maintained in MSCGM BulletKit
medium (Lonza). Cells were treated with recombinant FAM20C
or the viruses when they reach 80% confluence. For the gain-of-
function analyses, MC3T3-E1 cells were treated with mouse
recombinant FAM20C at the concentrations of 200 ng/ml,
400 ng/ml and 800 ng/ml. For the loss-of-function studies,
MC3T3-E1, Saos-2 and hMSC cells were infected with the mouse
or human shRNA-lentiviruses (all from Santa Cruz) containing a
mixture of three target-specific shRNA sequences against the
mouse or human FAM20C. A lentivirus expressing the scrambled
shRNA (with no specific target in the genome) served as the
control virus (Santa Cruz). The infection rate was monitored by
infecting these cells with another control virus (Santa Cruz)
expressing the GFP indicator. After 1-week selection with 5–8 mg/
ml concentrations of puromycin (Santa Cruz), the control virus
with GFP showed a nearly 100% infection rate. To induce
osteogenic differentiation for the MC3T3 cells and Saos-2 cells,
the culture medium was supplemented with 100 mg/ml ascorbic
acid, 10 mM b-glycerophosphate and 30 nM dexamethasone; the
osteogenic differentiation of human MSC was induced using the
Osteogenic BulletKit (Lonza) following the manufacturer’s in-
struction. Total RNA was extracted from the cells at different time
points. For the gain-of-function analyses, RNA was extracted after
3 weeks of induction. For the ‘‘shRNA knockdown’’ analyses,
RNA was extracted at 3 days after the lentiviral infection and
before the osteogenic medium (inducing the osteogenic differen-
tiation) addition, and at 1, 2 and 3 weeks after the start of
osteogenic induction. Real-time PCR was performed to evaluate
the mRNA levels of the selected genes. The mineral deposition
rate was determined by nodule formation and Alizarin red
concentration in each well were measured using the Osteogenesis
Quantitation kit (Millipore) for MC3T3-E1 cells treated with
recombinant FAM20C (the gain-of-function experiments).
MC3T3-E1 cells and hMSC cells infected with the FAM20C-
shRNA viruses became unhealthy (showing lot of cell death) after
4-week culture. The Saos-2 cells could not survive in the
osteogenic medium for longer than 2 weeks. The data collected
from the culture of cells at the ‘‘unhealthy stages’’ were discarded.
Statistics
The data are expressed as the mean 6 SD of at least 6
individual determinations in all experiments unless otherwise
indicated. We statistically evaluated the data employing ANOVA
to test for any differences among the sample groups. When a
difference was determined, 2-sample t tests were employed to
evaluate all possible pairs of samples.
Supporting Information
Table S1 Primers used for the real-time PCR (Q-PCR) analyses.
Primers for real-time PCR analyses on critical genes related to
biomineralization, osteoblast/osteocyte differentiation and phos-
phate homeostasis. The mRNA samples used for the real-time
PCR were extracted from human and mouse osteogenic cells,
mouse bone and mouse kidney.
(DOC)
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